Back to search results

Evaluating Anticoagulation Management During and After Pregnancy

This study, called PREP and GO, is looking at how different ways of managing blood thinners (anticoagulation) affect pregnant individuals who need them for blood clot (VTE) prevention or treatment. Specifically, it's focused on low-molecular-weight heparin (LMWH) use around labor, delivery, and the time after birth. The study wants to understand how these management strategies impact bleeding events, the risk of new blood clots, and the overall delivery experience. You might be able to join if you are a woman between 18 and 60 years old and need anticoagulation during pregnancy for a VTE, either one diagnosed during this pregnancy or a previous one. The main goal is to measure the occurrence of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) from delivery up to six weeks postpartum. The study is currently unclear on its recruitment status and plans to include 825 participants.

Study design
This is an observational study, meaning researchers will watch and collect information without providing specific interventions. It plans to include 825 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from delivery up to 6 weeks postpartum to measure bleeding events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05756244

PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

Recruiting
Not specifiedAges 18–60Observational
University of Calgary
~825 participants
Updated 2025-11-28 on ClinicalTrials.gov

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of MB and CRNMB
Measured over Delivery up to 6 weeks postpartum

Conditions

Pregnancy Related
Venous Thromboembolism

Explore related trials

Antiphospholipid SyndromePregnancyThrombophiliaVenous Thromboembolism

Where it's being run

14 sites across 9 states
Ontario4
Alberta2
Quebec2
North Carolina1
British Columbia1
Manitoba1
Denmark1
France1

Study leadership

  • Leslie Skeith, MD · PRINCIPAL_INVESTIGATOR · University of Calgary
  • Isabelle Malhamé, MD · PRINCIPAL_INVESTIGATOR · McGill University
  • Kinga Malinowski, MD · PRINCIPAL_INVESTIGATOR · University of Toronto

Who to contact

Jill Baxter, BSc
[email protected]
403-220-7103
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of:
Receiving any dose or type of LMWH during the antepartum period

Exclusion

Anticoagulation for a non-VTE indication, including prosthetic heart valves, atrial fibrillation, prevention of placenta-mediated pregnancy complications, or prevention of recurrent pregnancy loss (participants can be included with a diagnosis of antiphospholipid syndrome (APS) with or without thrombotic events)
Unable to provide or declined consent.
Home or birthing centre planned delivery.

What this trial measures

  • Incidence of MB and CRNMBDelivery up to 6 weeks postpartum

    To estimate the combined incidence of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) for the six most common antepartum strategies.